With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.
In January 2025, Wockhardt announced that ZAYNICH demonstrated unprecedented efficacy in a global, pivotal Phase III study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback